Last year, generic products in the market for eye drops with the active ingredient olopatadine, used to treat allergic conjunctivitis, posted a 24% year-over-year (YoY) increase in prescription sales. It is the most significant sales expansion since 2019.

The pharmaceutical industry anticipates a substantial expansion in prescription sales of generic olopatadine. In Q3 of last year, generic companies scored a win in a six-year-long patent dispute for ‘Pazeo 0.7% Eye Drops’. This means that they no longer have the burden of potential infringement of patent and compensation payments.

The prescription of olopatadine eye drops tends to increase in the second and third quarters when outdoor ac